Clinical use of a growth hormone receptor antagonist in the treatment of acromegaly.
dc.contributor.author | Drake, William M | |
dc.contributor.author | Parkinson, Craig | |
dc.contributor.author | Besser, G M | |
dc.contributor.author | Trainer, Peter J | |
dc.date.accessioned | 2009-09-22T11:02:08Z | |
dc.date.available | 2009-09-22T11:02:08Z | |
dc.date.issued | 2001-11 | |
dc.identifier.citation | Clinical use of a growth hormone receptor antagonist in the treatment of acromegaly. 2001, 12 (9):408-13 Trends Endocrinol. Metab. | en |
dc.identifier.issn | 1043-2760 | |
dc.identifier.pmid | 11595543 | |
dc.identifier.uri | http://hdl.handle.net/10541/82035 | |
dc.description.abstract | The elucidation of the mechanisms by which growth hormone (GH) interacts with its receptor has facilitated the design of compounds that function as GH-receptor antagonists. One such compound, B2036, has been conjugated to polyethylene glycol to produce a drug, pegvisomant, that has a powerful ability to lower circulating concentrations of insulin-like growth factor I (IGF-I), the principal mediator of GH action, in patients with acromegaly and to improve the symptoms and signs associated with GH excess. This article describes the mechanism of action of GH-receptor antagonists, reviews the preclinical and clinical data on the use of pegvisomant and discusses some of the challenges that lie ahead in judging the efficacy of a treatment that, unlike established therapies for acromegaly, does not aim to modify the underlying cause of acromegaly, namely excess GH secretion, but aims to lower serum IGF-I levels to normal. | |
dc.language.iso | en | en |
dc.subject.mesh | Acromegaly | |
dc.subject.mesh | Animals | |
dc.subject.mesh | Biological Markers | |
dc.subject.mesh | Human Growth Hormone | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Insulin-Like Growth Factor I | |
dc.subject.mesh | Receptors, Somatotropin | |
dc.title | Clinical use of a growth hormone receptor antagonist in the treatment of acromegaly. | en |
dc.type | Article | en |
dc.contributor.department | Department Endocrinology, St Bartholomew's Hospital, London, UK EC1A 7BE. | en |
dc.identifier.journal | Trends in Endocrinology and Metabolism | en |
html.description.abstract | The elucidation of the mechanisms by which growth hormone (GH) interacts with its receptor has facilitated the design of compounds that function as GH-receptor antagonists. One such compound, B2036, has been conjugated to polyethylene glycol to produce a drug, pegvisomant, that has a powerful ability to lower circulating concentrations of insulin-like growth factor I (IGF-I), the principal mediator of GH action, in patients with acromegaly and to improve the symptoms and signs associated with GH excess. This article describes the mechanism of action of GH-receptor antagonists, reviews the preclinical and clinical data on the use of pegvisomant and discusses some of the challenges that lie ahead in judging the efficacy of a treatment that, unlike established therapies for acromegaly, does not aim to modify the underlying cause of acromegaly, namely excess GH secretion, but aims to lower serum IGF-I levels to normal. |